PTLA News and Press, Portola Pharmaceuticals Inc. From 01/05/19

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Like action? What a week ahead with a cavalcade of companies due to present across ...

Portola Pharmaceuticals (PTLA) Q3 2018 Earnings Conference Call November 7, 2018 4:30 PM ET Executives Cara Miller - Vice President of Investor Relations and Corporate Communications Scott Garland - President and Chief Executive Officer Mardi Dier - Executive Vice President, Chie...

Portola Pharmaceuticals (NASDAQ: PTLA ) Q3 results ($M): Revenue: 14.2 (+273.7%); Andexxa sales: 7.7. More news on: Portola Pharmaceuticals, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

Portola Pharmaceuticals (NASDAQ: PTLA ): Q3 GAAP EPS of -$1.08 beats by $0.55 . Revenue of $14.2M (+273.7% Y/Y) beats by $7.2M . Shares -1.94% . Press Release More news on: Portola Pharmaceuticals, Earnings news and commentary, Healthcare stocks news,

– Third Quarter Andexxa Product Revenues of $7.7 Million – – Company Improves Financial Expectations for 2018 Operating Expenses – – Conference Call Today at 4:30 p.m. ET – SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- ...

AAOI , ADT , ALB , ALRM , AMBC , ANGI , ANSS , ARNA , ATO , AVID , AVLR , AYX , BREW , CABO , CARG , CASA , CISN , CSGS , CSOD , CTRP , CVNA , CYBR , DVA , ECPG , EDIT , ENS , ENV , ET , EVC , EVRG , FARM , FG , FLO , FLS , FOSL , GDOT , GKOS , HK , HO...

SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that the Company will participate in the following investor conferences in November and December: Credit Suisse’s 27 th Annual Healthcare Conferen...

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) announced today that on October 26, 2018, the Compensation Committee of the Board of Directors approved, effective as of October 31, 2018, the grant of an inducement stock opt...

– Differentiated Syk/JAK Inhibitor Studied in Patients with Heavily Pre-Treated T-Cell Malignancies –                – Also Accepted: Two Posters on Andexxa ® and an Oral Session on the Burden of Hospital Read...

NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA), Cable One, Inc. (NYSE:CAB...